This content is sponsored by AstraZeneca.
Because endocrine resistance inevitably develops during the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC), there is a need to identify alternative approaches to help prolong a patient’s time on endocrine therapy.1-3 Learn how integrating ESR1 mutation monitoring into routine blood tests during first-line treatment may help detect emerging endocrine resistance in some aBCs before disease progression and inform earlier treatment decisions.1,2
Learning Objectives:
- ESR1 mutations driving endocrine resistance during aromatase inhibitor exposure in HR+, HER2-negative aBC
- Clinical rationale for shifting from ESR1 mutation testing at disease progression to monitoring during first-line treatment using circulating tumor DNA
- How earlier detection of ESR1 mutations may identify patients at risk of disease progression and inform timely treatment adjustments
References:
1. Bidard FC et al. Lancet Oncol. 2022;23(11):1367-1377.
2. Turner N et al. Future Oncol. 2023;19(8):559-573.
3. Barrios CH. Presented at: SABCS, December 5-9, 2023.
©2026 AstraZeneca. All rights reserved. US-115630 Last Updated 9/26
